Transferrin-mediated iron sequestration as a novel therapy for bacterial and fungal infections

Current Opinion in Microbiology

Volumn 27, Issue , 2015, Pages 57-61

  Bruhn, Kevin W ^a   Spellberg, Brad ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON CHELATING AGENT; TRANSFERRIN; ANTIINFECTIVE AGENT; IRON;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIFUNGAL RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; CHELATION THERAPY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED PRACTICE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; IRON CHELATION; MEDIATOR; MYCOSIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; VALIDATION STUDY; ANIMAL; BACTERIAL INFECTIONS; CLINICAL TRIAL (TOPIC); DISEASE MODEL; METABOLISM; MYCOSES;

BACTERIA (MICROORGANISMS); MAMMALIA;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; IRON; IRON CHELATING AGENTS; MYCOSES; TRANSFERRIN;

EID: 84938856023     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2015.07.005     Document Type: Review

References (50)

1. Schaible U.E., Kaufmann S.H.E. Iron and microbial infection. Nat Rev Microbiol 2004, 2:946-953.
2. Skaar E.P. The battle for iron between bacterial pathogens and their vertebrate hosts. PLoS Pathog 2010, 6:e1000949.
3. Sutak R., Lesuisse E., Tachezy J., Richardson D.R. Crusade for iron: iron uptake in unicellular eukaryotes and its significance for virulence. Trends Microbiol 2008, 16:261-268.
4. Haley K.P., Skaar E.P. A battle for iron: host sequestration and Staphylococcus aureus acquisition. Microbes Infect 2012, 14:217-227.
5. Cassat J.E., Skaar E.P. Iron in infection and immunity. Cell Host Microbe 2013, 13:509-519.
6. Aguila A., Herrera A.G., Morrison D., Cosgrove B., Perojo A., Montesinos I., Pérez J., Sierra G., Gemmell C.G., Brock J.H. Bacteriostatic activity of human lactoferrin against Staphylococcus aureus is a function of its iron-binding properties and is not influenced by antibiotic resistance. FEMS Immunol Med Microbiol 2001, 31:145-152.
7. Ibrahim A.S., Gebermariam T., Fu Y., Lin L., Husseiny M.I., French S.W., Schwartz J., Skory C.D., Edwards J.E., Spellberg B.J. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007, 117:2649-2657.
8. De Léséleuc L., de Harris G., KuoLee R., Chen W. In vitro and in vivo biological activities of iron chelators and gallium nitrate against Acinetobacter baumannii. Antimicrob Agents Chemother 2012, 56:5397-5400.
9. Foley T.L., Simeonov A. Targeting iron assimilation to develop new antibacterials. Expert Opin Drug Discov 2012, 7:831-847.
10. Thompson M.G., Corey B.W., Si Y., Craft D.W., Zurawski D.V. Antibacterial activities of iron chelators against common nosocomial pathogens. Antimicrob Agents Chemother 2012, 56:5419-5421.
11. Fischbach M.A., Lin H., Liu D.R., Walsh C.T. How pathogenic bacteria evade mammalian sabotage in the battle for iron. Nat Chem Biol 2006, 2:132-138.
12. Caza M., Kronstad J.W. Shared and distinct mechanisms of iron acquisition by bacterial and fungal pathogens of humans. Front Cell Infect Microbiol 2013, 3:80.
13. Miethke M., Marahiel M.A. Siderophore-based iron acquisition and pathogen control. Microbiol Mol Biol Rev 2007, 71:413-451.
14. Wandersman C., Delepelaire P. Bacterial iron sources: from siderophores to hemophores. Annu Rev Microbiol 2004, 58:611-647.
15. Bernier G., Girijavallabhan V., Murray A., Niyaz N., Ding P., Miller M.J., Malouin F. Desketoneoenactin-siderophore conjugates for candida: evidence of iron transport-dependent species selectivity. Antimicrob Agents Chemother 2005, 49:241-248.
16. Dorsey C.W., Tomaras A.P., Connerly P.L., Tolmasky M.E., Crosa J.H., Actis L.A. The siderophore-mediated iron acquisition systems of Acinetobacter baumannii ATCC 19606 and Vibrio anguillarum 775 are structurally and functionally related. Microbiology 2004, 150:3657-3667.
17. Funahashi T., Tanabe T., Mihara K., Miyamoto K., Tsujibo H., Yamamoto S. Identification and characterization of an outer membrane receptor gene in Acinetobacter baumannii required for utilization of desferricoprogen, rhodotorulic acid, and desferrioxamine B as xenosiderophores. Biol Pharm Bull 2012, 35:753-760.
18. Haas H. Molecular genetics of fungal siderophore biosynthesis and uptake: the role of siderophores in iron uptake and storage. Appl Microbiol Biotechnol 2003, 62:316-330.
19. Heymann P., Gerads M., Schaller M., Dromer F., Winkelmann G., Ernst J.F. The siderophore iron transporter of Candida albicans (Sit1p/Arn1p) mediates uptake of ferrichrome-type siderophores and is required for epithelial invasion. Infect Immun 2002, 70:5246-5255.
20. Lee J.-H., Han Y. Candida albicans can utilize siderophore during candidastasis caused by apotransferrin. Arch Pharm Res 2006, 29:249-255.
21. Noble S.M. Candida albicans specializations for iron homeostasis: from commensalism to virulence. Curr Opin Microbiol 2013, 16:708-715.
22. Cappellini M.D., Cohen A., Piga A., Bejaoui M., Perrotta S., Agaoglu L., Aydinok Y., Kattamis A., Kilinc Y., Porter J., et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 2006, 107:3455-3462.
23. Vichinsky E. Clinical application of deferasirox: practical patient management. Am J Hematol 2008, 83:398-402.
24. Gordeuk V.R., Thuma P.E., Brittenham G.M., Biemba G., Zulu S., Simwanza G., Kalense P., M'Hango A., Parry D., Poltera A.A., et al. Iron chelation as a chemotherapeutic strategy for Falciparum malaria. Am J Trop Med Hyg 1993, 48:193-197.
25. Santos L.S.A., Sodre L.C., Valle S.R., Silva A.B., Abi-chacra A.E., Silva V.L., Souza-Goncalves L.A., Sangenito S.L., Goncalves S.D., Souza O.P.L., et al. Antimicrobial action of chelating agents: repercussions on the microorganism development, virulence and pathogenesis. Curr Med Chem 2012, 19:2715-2737.
26. Spellberg B., Ibrahim A.S., Chin-Hong P.V., Kontoyiannis D.P., Morris M.I., Perfect J.R., Fredricks D., Brass E.P. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012, 67:715-722.
27. Gkouvatsos K., Papanikolaou G., Pantopoulos K. Regulation of iron transport and the role of transferrin. Biochim Biophys Acta 2012, 1820:188-202.
28. Gambino R., Desvarieux E., Orth M., Matan H., Ackattupathil T., Lijoi E., Wimmer C., Bower J., Gunter E. The relation between chemically measured total iron-binding capacity concentrations and immunologically measured transferrin concentrations in human serum. Clin Chem 1997, 43:2408-2412.
29. Sridhar S., Ahluwalia M., Brummer E., Stevens D.A. Characterization of an anticryptococcal protein isolated from human serum. Infect Immun 2000, 68:3787-3791.
30. Watanabe T., Tanaka H., Nakao N., Mikami T., Suzuki M., Matsumoto T. Anti Candida activity of induced transferrin in mice immunized with inactivated Candida albicans. Biol Pharm Bull 1997, 20:637-640.
31. Hunter R.L., Bennett B., Towns M., Vogler W.R. Transferrin in disease II: defects in the regulation of transferrin saturation with iron contribute to susceptibility to infection. Am J Clin Pathol 1984, 81:748-753.
32. McDonald C.J., Jones M.K., Wallace D.F., Summerville L., Nawaratna S., Subramaniam V.N. Increased iron stores correlate with worse disease outcomes in a mouse model of schistosomiasis infection. PLoS ONE 2010, 5:e9594.
33. Sawatzki G., Hoffmann F.A., Kubanek B. Acute iron overload in mice: pathogenesis of Salmonella typhimurium infection. Infect Immun 1983, 39:659-665.
34. Schaible U.E., Collins H.L., Priem F., Kaufmann S.H.E. Correction of the iron overload defect in β-2-microglobulin knockout mice by lactoferrin abolishes their increased susceptibility to tuberculosis. J Exp Med 2002, 196:1507-1513.
35. Bezkorovainy A. Antimicrobial properties of iron-binding proteins. Adv Exp Med Biol 1981, 135:139-154.
36. Brandsma M.E., Jevnikar A.M., Ma S. Recombinant human transferrin: beyond iron binding and transport. Biotechnol Adv 2011, 29:230-238.
37. Bullen J.J., Rogers H.J., Spalding P.B., Ward C.G. Natural resistance, iron and infection: a challenge for clinical medicine. J Med Microbiol 2006, 55:251-258.
38. Brandsma M.E., Diao H., Wang X., Kohalmi S.E., Jevnikar A.M., Ma S. Plant-derived recombinant human serum transferrin demonstrates multiple functions. Plant Biotechnol J 2010, 8:489-505.
39. Lawrence T.H., Biggers C.J., Simonton P.R. Bacteriostatic inhibition of Klebsiella pneumoniae by three human transferrins. Ann Hum Biol 1977, 4:281-284.
40. Salamah A.A., Al-Obaidi A.S. Effect of some physical and chemical factors on the bactericidal activity of human lactoferrin and transferrin against Yersinia pseudotuberculosis. New Microbiol 1995, 18:275-281.
41. Rooijakkers S.H.M., Rasmussen S.L., McGillivray S.M., Bartnikas T.B., Mason A.B., Friedlander A.M., Nizet V. Human transferrin confers serum resistance against Bacillus anthracis. J Biol Chem 2010, 285:27609-27613.
42. Shiraishi A., Arai T. Antifungal activity of transferrin. Sabouraudia 1979, 17:79-83.
43. Sutcliffe M.C., Savage A.M., Alford R.H. Transferrin-dependent growth inhibition of yeast-phase Histoplasma capsulatum by human serum and lymph. J Infect Dis 1980, 142:209-219.
44. Lin L., Pantapalangkoor P., Tan B., Bruhn K.W., Ho T., Nielsen T., Skaar E.P., Zhang Y., Bai R., Wang A., et al. Transferrin iron starvation therapy for lethal bacterial and fungal infections. J Infect Dis 2014, 210:254-264.
45. Bird L.J., Bonnefoy V., Newman D.K. Bioenergetic challenges of microbial iron metabolisms. Trends Microbiol 2011, 19:330-340.
46. Abe F., Katoh T., Inaba H., Hotchi M. Experimental candidiasis associated with liver injury. Role of transferring. Mycopathologia 1988, 104:3-6.
47. Spratt B.G. Resistance to antibiotics mediated by target alterations. Science 1994, 264:388-393.
48. Sahlstedt L., von Bonsdorff L., Ebeling F., Ruutu T., Parkkinen J. Effective binding of free iron by a single intravenous dose of human apotransferrin in haematological stem cell transplant patients. Br J Haematol 2002, 119:547-553.
49. Von Bonsdorff L., Sahlstedt L., Ebeling F., Ruutu T., Parkkinen J. Apotransferrin administration prevents growth of Staphylococcus epidermidis in serum of stem cell transplant patients by binding of free iron. FEMS Immunol Med Microbiol 2003, 37:45-51.
50. Parkkinen J., Sahlstedt L., Von Bonsdorff L., Salo H., Ebeling F., Ruutu T. Effect of repeated apotransferrin administrations on serum iron parameters in patients undergoing myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2006, 135:228-234.